Evidence map›Paper›PMID 25625929›Full record

ReviewHuman vaccines & immunotherapeutics2014

Tumor cell lysates as immunogenic sources for cancer vaccine design.

Fermín E González, Alejandra Gleisner, Felipe Falcón-Beas, Fabiola Osorio, Mercedes N López, Flavio Salazar-Onfray

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Fermín E Gonzáleza Millennium Institute on Immunology and Immunotherapy; Institute of Biomedical Sciences; Faculty of Medicine ; University of Chile ; Santiago , Chile.
Alejandra Gleisner
Felipe Falcón-Beas
Fabiola Osorio
Mercedes N López
Flavio Salazar-Onfray

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous dendritic cells (DCs) loaded with tumor-associated antigens (TAAs) are a promising immunological tool for cancer therapy. These stimulate the antitumor response and immunological memory generation. Nevertheless, many patients remain refractory to DC approaches. Antigen (Ag) delivery to DCs is relevant to vaccine success, and antigen peptides, tumor-associated proteins, tumor cells, autologous tumor lysates, and tumor-derived mRNA have been tested as Ag sources. Recently, DCs loaded with allogeneic tumor cell lysates were used to induce a potent immunological response. This strategy provides a reproducible pool of almost all potential Ags suitable for patient use, independent of MHC haplotypes or autologous tumor tissue availability. However, optimizing autologous tumor cell lysate preparation is crucial to enhancing efficacy. This review considers the role of cancer cell-derived lysates as a relevant source of antigens and as an activating factor for ex vivo therapeutic DCs capable of responding to neoplastic cells. These promising therapies are associated with the prolonged survival of advanced cancer patients.

Indexed as

Antigens, NeoplasmCancer VaccinesCell ExtractsDendritic CellsHumansImmunologic MemoryNeoplasmsT-Lymphocytes, CytotoxicAntigens, NeoplasmCancer VaccinesCell ExtractsAgs, AntigensAM, Cytokine-activated monocytescancer immunotherapyCDAMs, Cell death-associated moleculesCRT, CalreticulinCTLs, Cytotoxic T lymphocytesDAMPsDAMPs, Damage-associated molecular patternsDCs, Dendritic cellsdendritic cellsDTH, Delayed-type IV hypersensitivityGM-CSF, Granulocyte and macrophage colony stimulating factorHMGB1, High-mobility group box 1 proteinHSPs, Heat shock proteinsICD, Immunogenic cell deathimmunogenic cell deathMAAs, Melanoma-associated antigensMHC, Major histocompatibility complexMM, Malignant melanomaNKT, Natural killer T cellPAMPs, Pathogen-associated molecular patternsPBMCs, Peripheral blood mononuclear cellsPCCL, Prostate cancer cell lysatePD1, Programmed cell death protein 1PRRs, Pattern recognition receptorsPSA, Prostate specific antigenRAGE, Receptor for advanced glycation endproductsSNPs, Single nucleotide polymorphismsTAAs, Tumor-associated antigensTAPCells, Tumor antigen presenting cellsTCRs, T cell receptorsTLRs, Toll-like receptorsTNF, Tumor necrosis factorToll-like receptorsTregs, Regulatory T lymphocytesTRIMEL, Allogeneic melanoma cell lysateTRIPRO, Allogeneic prostate cell lysate

Identifiers

PMID25625929
PMCPMC4514089

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.